Drugs / AAV-MECP2
AAV-MECP2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06856759 | Jan 2025 → Oct 2026 expected | Rett syndrome | Guangzhou Women and Children's Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV-MECP2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06856759 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV-MECP2 gene therapy product for RTT” NCT06856759 ↗ |
| Route | Intrathecal | “Administration route: intrathecal injection” NCT06856759 ↗ |
| Target | MECP2 | “recombinant AAV gene therapy vector containing neuron specific promoter (CAG) driven MECP2” NCT06856759 ↗ |